Uncategorized

AnCan GU ASCO26 survivorship poster: participants strongly endorse our Groups – 99% recommend AnCan Groups.

Telehealth gets extended through 2027! Patients welcome teh return of more liberal telehealth rules with Feb 3, 2026 legislation. But there are still glitches!

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 2/16/26: Pros & Cons of Estradiol (E2) as primary and complementary ADT… & mustard!

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 2/10/26: Cribriform complicates treatment decision; and we discuss NCI trial

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 2/2/26: Unrelated Newbies from either Coast have almost identical issues.

“Playing the Long Game” – Does your Recurrent/Advanced Prostate Cancer Need Treating?: a new category of prostate cancer PSMA Positive Biochemically Recurrent – PSMA+ BCR emerges; “it’s like listening 15 years ago to the folks who began to promote active surveillance ( in first line treatment)”

Hi-Risk/Recurrent/Advanced PrCa Video Chat 1/27/26: Disruptor attends solely to advocate for Dr. Kwon… and makes AnCan’s case with his own inappropriate overtreatment.

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 1/19/26: After 15 years, Prostate cancer recurs for one Gent; and the 2nd time, 13 years later, for another.

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 1/13/26: Denovo metastatic BRCA2 Newbie stumps us all!

Hi-Risk/Recurrent/Advanced PrCa Video Chat, 1/5/26: Like London buses, topics come in clusters this week – post-surgery recurrence, and monotherapy daro

Hi-Risk/Recurrent/Advanced PrCa Video Chat, Dec 23, 2025: AFib may dictate use of ARSI – 2nd line anti-androgen

FDA Position on Cannabis and Cannabinoids interpreted by an AnCan peer expert.